ImmunityBio Expands Global Reach with UAE Approval for ANKTIVA
ImmunityBio, Inc., a pioneering biotechnology company, recently announced the Emirates Drug Establishment’s (EDE) approval of ANKTIVA® (nogapendekin alfa inbakicept) for two significant indications. This regulatory milestone enhances ANKTIVA’s availability to patients in the UAE and marks a critical step in its global expansion.
Expanding Regulatory Reach
With the UAE’s recent approval, ANKTIVA is now authorized in a total of 34 countries, reflecting a growing global regulatory foothold. This latest approval is particularly noteworthy as it represents the first worldwide authorization that encompasses the entire spectrum of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Specifically, it addresses carcinoma in situ (CIS), which may present with or without papillary tumors, along with isolated papillary disease.
Comprehensive Treatment for NMIBC and NSCLC
The EDE’s approval covers two distinct presentations of ANKTIVA. The 0.4 mg formulation is indicated for use in conjunction with Bacillus Calmette-Guérin (BCG) to treat adult patients with BCG-unresponsive NMIBC. Meanwhile, the 1.2 mg formulation is approved for inclusion with immune checkpoint inhibitors to treat adults suffering from metastatic non-small cell lung cancer (NSCLC) who have already experienced disease progression after standard therapies.
Clinical trials have shown promising results for both indications. In the QUILT-3.032 trial for NMIBC, ANKTIVA in combination with BCG achieved a complete response rate of 71% among patients with CIS, while the 12-month disease-free survival rate for papillary disease without CIS was recorded at 58.2%. Similarly, in the QUILT-3.055 trial for NSCLC, patients who were checkpoint-refractory showed a median overall survival of 14.6 months.
Meeting Unmet Medical Needs
The approval of ANKTIVA is particularly significant as it addresses critical gaps in treatment options for patients with BCG-unresponsive NMIBC and checkpoint-refractory NSCLC. Traditionally, individuals facing BCG therapy failures faced limited choices, often leading to radical cystectomy. The introduction of ANKTIVA provides an alternative immunotherapeutic approach, improving the chances of meaningful outcomes for these patients.
Moreover, the combination of ANKTIVA with checkpoint inhibitors has demonstrated potential in reviving immune responses in advanced NSCLC, where patients have limited options following standard care. This innovative treatment strategy aims to restore the immune system’s ability to confront malignancies that have advanced beyond initial therapies.
Clinical Evidence and Future Implications
The robust clinical evidence backing these approvals underline ANKTIVA’s efficacy in both NMIBC and NSCLC. The results from pivotal studies, such as QUILT-3.032 and QUILT-3.055, have further established ANKTIVA’s safety profile, with most reported adverse effects being mild.
Looking ahead, ImmunityBio plans to broaden access to ANKTIVA throughout the Gulf region in collaboration with local partners, thereby enhancing treatment availability where it’s most needed. This strategic move is poised to position ANKTIVA as a key player in managing bladder and lung cancers.
In conclusion, ImmunityBio’s recent authorization for ANKTIVA in the UAE marks a significant advancement in cancer treatment options for patients worldwide. With its innovative mechanism targeting the immune system, ANKTIVA represents a transformative leap in the ongoing fight against resistant forms of cancer.